中国原创药1类新药成功克服“慢粒”耐药

中国新闻网2022-11-28

中新网上海11月28日电（记者陈静）中国医药企业原创1类新药耐立克®上市，将有望改变全球“慢粒”治疗格局。　　据了解，耐立克®从临床开发到最终上市都由本土团队完成。上市来，耐立克®的临床数据不断得到验证，已成为广大血液科医生战胜“耐药“的武器。今年上半年，耐立克®获中国临床肿瘤学会（CSCO）指南和中国抗癌协会《中国肿瘤整合诊治指南（CACA）》推荐，治疗既往TKI耐药慢粒患者。　　耐立克...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2286883557?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-11-28 13:22","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2286883557","market":"sh","top_or_hot":-1,"title":"中国原创药1类新药成功克服“慢粒”耐药","media":"中国新闻网","content":"<div>\n<p>中新网上海11月28日电 （记者 陈静）中国医药企业原创1类新药耐立克®上市，将有望改变全球“慢粒”治疗格局。\n　　据了解，耐立克®从临床开发到最终上市都由本土团队完成。上市来，耐立克®的临床数据不断得到验证，已成为广大血液科医生战胜“耐药“的武器。今年上半年，耐立克®获中国临床肿瘤学会（CSCO）指南和中国抗癌协会《中国肿瘤整合诊治指南（CACA）》推荐，治疗既往TKI耐药慢粒患者。\n　　耐立克...</p>\n\n<a href=\"https://finance.sina.com.cn/chanjing/cyxw/2022-11-28/doc-imqqsmrp7826447.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国原创药1类新药成功克服“慢粒”耐药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国原创药1类新药成功克服“慢粒”耐药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-28 13:22 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/chanjing/cyxw/2022-11-28/doc-imqqsmrp7826447.shtml><strong>中国新闻网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中新网上海11月28日电 （记者 陈静）中国医药企业原创1类新药耐立克®上市，将有望改变全球“慢粒”治疗格局。\n　　据了解，耐立克®从临床开发到最终上市都由本土团队完成。上市来，耐立克®的临床数据不断得到验证，已成为广大血液科医生战胜“耐药“的武器。今年上半年，耐立克®获中国临床肿瘤学会（CSCO）指南和中国抗癌协会《中国肿瘤整合诊治指南（CACA）》推荐，治疗既往TKI耐药慢粒患者。\n　　耐立克...</p>\n\n<a href=\"https://finance.sina.com.cn/chanjing/cyxw/2022-11-28/doc-imqqsmrp7826447.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4525","symbol_name":"远程办公概念","start_time":0,"source_url":"https://finance.sina.com.cn/chanjing/cyxw/2022-11-28/doc-imqqsmrp7826447.shtml","article_id":"2286883557","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/chanjing/cyxw/2022-11-28/doc-imqqsmrp7826447.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2286883557","pubTimestamp":1669612920,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"中新网上海11月28日电 中国医药企业原创1类新药耐立克上市，将有望改变全球“慢粒”治疗格局。　　耐立克中国临床试验主要研究者、北京大学血液病研究所江倩教授对记者表示，克服耐药是慢粒治疗的“刚需”，从首例使用耐立克的患者入组迄今已6年有余，耐立克也已上市一周年，患者从耐立克中获益颇多。　　据透露，经过一年的努力，截至2022年10月底，耐立克已获得52个城市、15个省份的惠民保报销资格。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4525":"远程办公概念","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","SG9999001424.SGD":"United E-Commerce Fund SGD","BK4527":"明星科技股","BK4020":"通信设备","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4579":"人工智能","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","BK4550":"红杉资本持仓","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","CSCO":"思科","LU0731783394.SGD":"Fidelity Global Dividend A-MINCOME(G)-SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK4581":"高盛持仓","BK4560":"网络安全概念","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4515":"5G概念","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Class 1 new drugs of Chinese original drugs successfully overcome \"CML\" drug resistance","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CACA":1,"CSCO":1},"content_text":"中新网上海11月28日电 （记者 陈静）中国医药企业原创1类新药耐立克®上市，将有望改变全球“慢粒”治疗格局。\n　　据了解，耐立克®从临床开发到最终上市都由本土团队完成。上市来，耐立克®的临床数据不断得到验证，已成为广大血液科医生战胜“耐药“的武器。今年上半年，耐立克®获中国临床肿瘤学会（CSCO）指南和中国抗癌协会《中国肿瘤整合诊治指南（CACA）》推荐，治疗既往TKI耐药慢粒患者。\n　　耐立克®中国临床试验主要研究者、北京大学血液病研究所江倩教授对记者表示，克服耐药是慢粒治疗的“刚需”，从首例使用耐立克®的患者入组迄今已6年有余，耐立克®也已上市一周年，患者从耐立克®中获益颇多。她期待耐立克®能够拓展更多的适应症，能够惠及更多的血液病患者。\n　　中国医学科学院血液病医院王建祥教授认为，耐立克®有着光明的应用前景，不只是对慢粒，还有对相关急性淋巴细胞白血病等等。\n　　华中科技大学同济医学院附属协和医院胡豫教授亦表示：耐立克®对血液科医生临床意义重大，它的价值绝不仅仅局限于慢粒患者。\n　　据透露，经过一年的努力，截至2022年10月底，耐立克已获得52个城市、15个省份的惠民保报销资格。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：李昂","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2286883557"}